Huntington's Disease - Competitive Landscape in 2021
GlobalData’s Huntington's Disease - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Huntington’s disease (HD) protein is a major target of drug developers. There are 138 drugs in the pipeline, 99% 0f which are in early-stage. Mid-sized Pharma companies dominates R&D in this indication. The addition of improved asymptomatic treatments and potential disease-modifying drugs for HD is expected to drive market growth.
This reports provides a data-driven overview of the current and future competitive landscape in HD therapeutics.
Components of the report include -
Reasons to Buy
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HD in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
1.Table of Contents1.1 Preface1.2 Abbreviations1.3 Related Reports 1.4 Upcoming Related Reports2 Executive Summary2.1 Key Findings2.2 Key Events3 Introduction3.1 Report Scope3.2 Disease Overview Epidemiology Overview3.3 Epidemiology 4 Marketed Drugs Assessment4.1 Marketed Drugs Overview4.2 Marketed Drug Profiles5 Pipeline Assessment5.1 Pipeline Overview5.2 Pipeline Breakdown by Region5.3 Pipeline Breakdown by Molecule Type and Target5.4 Drug Review Designations5.5 Phase Transition Success Rates5.6 Likelihood of Approval6 Clinical Trial Assessment6.1 Clinical Trials Overview by Phase6.2 Overview by Region 6.4 Therapy Area Perspective6.4 Leading Sponsors6.5 Enrollment Analytics6.6 Feasibility Analysis7 Commercial Assessment7.1 Upcoming Market Catalysts8 Social Media and Digital Marketing8.1 Key Twitter Chatter8.2 Top Branded Websites8.3 Trust Flow and Citation Flow9 Appendix9.1 Methodology9.2 About the Authors9.3 About GlobalData9.4 Contact Us9.5 Disclaimer